Ribavirin is one of two components of a combination therapy approved last year by the Food and Drug Administration for treatment of hepatitis C. Prison system health-care officials decided in June to begin treating prisoners with the combination therapy after a study showed that 29 percent of the state's inmates, or about 42,000 prisoners, were infected with the potentially lethal liver virus.
 Responding to reports that the highly-touted anticancer drug endostatin has failed to impress in its first human tests, Dr. Judah Folkman of Children Hospital in Boston told thousands of cancer specialists Monday that he was very pleased with the drug's early trials in Boston and hinted there will be more good news ahead.
 The Food and Drug Administration on Wednesday approved a powerful combination of two antiviral drugs to treat chronic hepatitis C, a liver infection that can lead to cirrhosis, liver cancer and liver failure.
Fisher's Specialized Pharmacy Services in Pittsburgh has announced plans to fill prescriptions nationwide for the anti-viral drug ribavirin, used by growing numbers of hepatitis C patients in combination with the drug interferon.
 One of the drugs used to control multiple sclerosis also sharply slows the rate at which people develop the crippling nerve disease, according to researchers.
 U.S. doctors said that a combination of two virus-fighting drugs has proved considerably more effective against chronic hepatitis C infections than the standard single medicine, said the Washington Post.
